RTW INVESTMENTS, LLC
13F Reported Value
ⓘ$11.7B
Holdings
84
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
RTW INVESTMENTS, LLC disclosed 84 positions worth $11.7B in its Form 13F-HR for Q2 2026, led by $MDGL (MADRIGAL PHARMACEUTICALS, INC.) at 9.1% of the equity portfolio, followed by $ARGX and $PTCT. During the quarter the fund opened 9 new positions and exited 13 — including a new stake in $KLRA and a full exit from $APGE. The portfolio is most concentrated in Healthcare (99.3% of disclosed assets). All figures are sourced directly from RTW INVESTMENTS, LLC’s Form 13F-HR filing with the SEC under CIK 1493215.
AI Fund Analysis
Diversifying
$MDGL
$ARGX
$PTCT
$PTGX
$CGON
$RDNT
$CMPS
$IMTX
$TARS
$REPLSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 40.7#2,092
Quality
$1.1B1,993,687 sh - —
Quality
$658.2M709,446 sh - 35.4#2,306
Quality
$631.9M7,746,415 sh - 59.4
Quality
$620.4M5,061,175 sh - 27.0
Quality
$605.0M8,514,590 sh - 39.4
Quality
$516.3M4,842,880 sh - 17.6
Quality
$434.5M13,900,620 sh - —
Quality
$377.5M4,251,996 sh - —
Quality
$345.8M3,304,903 sh - —
Quality
$328.8M17,946,754 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.$MDGL | 40.7#2,092 | $1.1B | 1,993,687 |
| ARGENX SE$ARGX | — | $658.2M | 709,446 |
| PTC THERAPEUTICS, INC.$PTCT | 35.4#2,306 | $631.9M | 7,746,415 |
| Protagonist Therapeutics, Inc$PTGX | 59.4 | $620.4M | 5,061,175 |
| CG Oncology, Inc.$CGON | 27.0 | $605.0M | 8,514,590 |
 INSMED Inc$INSM | 39.4 | $516.3M | 4,842,880 |
 Tango Therapeutics, Inc.$TNGX | 17.6 | $434.5M | 13,900,620 |
 Spyre Therapeutics, Inc.$SYRE | — | $377.5M | 4,251,996 |
 Celcuity Inc.$CELC | — | $345.8M | 3,304,903 |
 Erasca, Inc.$ERAS | — | $328.8M | 17,946,754 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of RTW INVESTMENTS, LLC's 84 positions.
Showing top 10 of 84 holdings.
Sector Allocation
Healthcare
$11.6B
Technology
$85.3M
Full Holdings — RTW INVESTMENTS, LLC (Q2 2026)
All 84 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $1.1B | 9.1% | +0% | 40.7 |
| 2 | $ARGX | ARGENX SE | $658.2M | 5.6% | +0% | — |
| 3 | $PTCT | PTC THERAPEUTICS, INC. | $631.9M | 5.4% | +0% | 35.4 |
| 4 | $PTGX | Protagonist Therapeutics, Inc | $620.4M | 5.3% | +0% | 59.4 |
| 5 | $CGON | CG Oncology, Inc. | $605.0M | 5.2% | +22% | 27 |
| 6 | $INSM | INSMED Inc | $516.3M | 4.4% | +0% | 39.4 |
| 7 | $TNGX | Tango Therapeutics, Inc. | $434.5M | 3.7% | +5% | 17.6 |
| 8 | $SYRE | Spyre Therapeutics, Inc. | $377.5M | 3.2% | +2% | — |
| 9 | $CELC | Celcuity Inc. | $345.8M | 3.0% | +9% | — |
| 10 | $ERAS | Erasca, Inc. | $328.8M | 2.8% | +11% | — |
| 11 | $RDNT | RadNet, Inc. | $298.9M | 2.5% | +13% | 58.6 |
| 12 |  $ORKA | Oruka Therapeutics, Inc. | $298.7M | 2.5% | +53% | — |
| 13 |  $NTRA | Natera, Inc. | $271.4M | 2.3% | -20% | 53.5 |
| 14 |  $RARE | Ultragenyx Pharmaceutical Inc. | $260.3M | 2.2% | +114% | 34.2 |
| 15 |  $IRTC | iRhythm Holdings, Inc. | $259.6M | 2.2% | +31% | 54.8 |
| 16 |  $CYTK | CYTOKINETICS INC | $243.8M | 2.1% | +5% | 28.1 |
| 17 |  $KLRA | Kailera Therapeutics, Inc. | $237.4M | 2.0% | NEW | — |
| 18 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $227.9M | 1.9% | +0% | 33.9 |
| 19 |  $GH | Guardant Health, Inc. | $222.2M | 1.9% | +0% | 39 |
| 20 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $213.7M | 1.8% | +19% | 76.5 |
| 21 | $TARS | Tarsus Pharmaceuticals, Inc. | $211.3M | 1.8% | +0% | 55 |
| 22 |  $STOK | Stoke Therapeutics, Inc. | $184.0M | 1.6% | +0% | 24.9 |
| 23 |  $QURE | uniQure N.V. | $181.5M | 1.6% | +52% | — |
| 24 |  $ACAD | ACADIA PHARMACEUTICALS INC | $180.8M | 1.5% | +0% | 67.8 |
| 25 |  $RGEN | REPLIGEN CORP | $169.3M | 1.4% | +3% | 58.4 |
| 26 |  $URGN | UroGen Pharma Ltd. | $167.2M | 1.4% | +0% | — |
| 27 |  $GHRS | GH Research PLC | $159.5M | 1.4% | +0% | — |
| 28 |  $IMCR | Immunocore Holdings plc | $154.6M | 1.3% | +0% | — |
| 29 | $CMPS | COMPASS Pathways plc | $151.4M | 1.3% | +1% | — |
| 30 | $IMTX | Immatics N.V. | $131.1M | 1.1% | +1% | — |
| 31 |  $ZLAB | Zai Lab Ltd | $124.9M | 1.1% | +0% | — |
| 32 |  $IMVT | Immunovant, Inc. | $122.4M | 1.1% | +0% | — |
| 33 |  $BLTE | BELITE BIO, INC | $110.2M | 0.9% | +0% | — |
| 34 |  $XNCR | Xencor Inc | $109.1M | 0.9% | +0% | 11.6 |
| 35 |  $TSHA | Taysha Gene Therapies, Inc. | $92.3M | 0.8% | -1% | 4.9 |
| 36 |  $COGT | Cogent Biosciences, Inc. | $89.4M | 0.8% | -58% | — |
| 37 |  $ALKS | Alkermes plc. | $87.6M | 0.8% | +0% | — |
| 38 |  $GPCR | Structure Therapeutics Inc. | $86.3M | 0.7% | NEW | — |
| 39 | $REPL | Replimune Group, Inc. | $82.0M | 0.7% | +1% | — |
| 40 |  $CSTL | CASTLE BIOSCIENCES INC | $66.3M | 0.6% | +1% | 40.7 |
| 41 |  $CADL | Candel Therapeutics, Inc. | $66.1M | 0.6% | +0% | — |
| 42 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $60.5M | 0.5% | +0% | — |
| 43 |  $KOD | Kodiak Sciences Inc. | $58.0M | 0.5% | +0% | — |
| 44 |  $AKTS | Aktis Oncology, Inc. | $51.3M | 0.4% | +0% | — |
| 45 |  $AXGN | Axogen, Inc. | $46.7M | 0.4% | NEW | 40.8 |
| 46 |  $DHR | DANAHER CORP /DE/ | $43.8M | 0.4% | NEW | 64.8 |
| 47 |  $CGEM | Cullinan Therapeutics, Inc. | $43.1M | 0.4% | +39% | — |
| 48 |  $NGNE | Neurogene Inc. | $42.8M | 0.4% | +0% | 27.4 |
| 49 |  $HNGE | Hinge Health, Inc. | $41.5M | 0.3% | -74% | 74.9 |
| 50 |  $OBIO | Orchestra BioMed Holdings, Inc. | $41.2M | 0.3% | +15% | 32 |
| 51 |  $SLDB | Solid Biosciences Inc. | $38.9M | 0.3% | NEW | — |
| 52 |  $SVRA | Savara Inc | $36.7M | 0.3% | +0% | — |
| 53 |  $AQST | Aquestive Therapeutics, Inc. | $30.9M | 0.3% | +0% | 14.5 |
| 54 |  $KYMR | Kymera Therapeutics, Inc. | $27.5M | 0.2% | +0% | 28.4 |
| 55 |  $VSTM | Verastem, Inc. | $25.3M | 0.2% | +1% | 29.7 |
| 56 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $24.2M | 0.2% | +0% | 22.6 |
| 57 |  $BBNX | Beta Bionics, Inc. | $23.5M | 0.2% | -25% | 29.8 |
| 58 |  $IPSC | Century Therapeutics, Inc. | $21.3M | 0.2% | +0% | 33.5 |
| 59 |  $EVMN | Evommune, Inc. | $20.0M | 0.2% | +0% | 14.9 |
| 60 |  $BEAM | Beam Therapeutics Inc. | $19.6M | 0.2% | +0% | 34.2 |
| 61 |  $DFTX | Definium Therapeutics, Inc. | $18.8M | 0.2% | +33% | — |
| 62 |  $IDYA | IDEAYA Biosciences, Inc. | $13.8M | 0.1% | NEW | 36.1 |
| 63 |  $ATAI.R1840904 | Atai Beckley N.V. | $10.5M | 0.1% | +0% | — |
| 64 |  $MIST | Milestone Pharmaceuticals Inc. | $10.5M | 0.1% | +24% | — |
| 65 |  $OCGN | Ocugen, Inc. | $10.2M | 0.1% | +0% | — |
| 66 |  $TENX | TENAX THERAPEUTICS, INC. | $10.1M | 0.1% | +88% | — |
| 67 |  $HTFL | Heartflow, Inc. | $8.7M | 0.1% | -40% | 34.3 |
| 68 |  $FRNM | Freenome, Inc. | $8.1M | 0.1% | +0% | — |
| 69 |  $WVE | Wave Life Sciences, Inc. | $7.8M | 0.1% | +0% | 7.5 |
| 70 |  $LRMR | Larimar Therapeutics, Inc. | $7.8M | 0.1% | +71% | — |
| 71 |  $LMRI | Lumexa Imaging Holdings, Inc. | $7.3M | 0.1% | +0% | — |
| 72 |  $ALLO | Allogene Therapeutics, Inc. | $6.8M | 0.1% | NEW | 33.9 |
| 73 |  $CBIO | CRESCENT BIOPHARMA, INC. | $6.7M | 0.1% | +0% | 9.6 |
| 74 |  $FDMT | 4D Molecular Therapeutics, Inc. | $6.3M | 0.1% | +0% | 34.5 |
| 75 |  $MAZE | Maze Therapeutics, Inc. | $6.3M | 0.1% | NEW | 10.3 |
| 76 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $6.0M | 0.1% | +0% | 13.6 |
| 77 |  $KLRS | Kalaris Therapeutics, Inc. | $5.3M | 0.1% | +0% | — |
| 78 |  $ABVX | Abivax S.A. | $3.5M | 0.0% | NEW | — |
| 79 |  $AVTX | Avalo Therapeutics, Inc. | $3.2M | 0.0% | -80% | 11.7 |
| 80 |  $MDLN | Medline Inc. | $2.8M | 0.0% | +0% | 62.5 |
| 81 |  $IRON | Disc Medicine, Inc. | $2.2M | 0.0% | +0% | — |
| 82 |  $IMA | ImageneBio, Inc. | $2.0M | 0.0% | +0% | 6.6 |
| 83 |  $XGN | EXAGEN INC. | $906,750 | 0.0% | -51% | 27.3 |
| 84 | $RCKT | ROCKET PHARMACEUTICALS, INC. | $1,190 | 0.0% | +0% | — |
New Positions (9)
Exited Positions (13)
$APGE Apogee Therapeutics, Inc.
$APLS Apellis Pharmaceuticals, Inc.
$ISRG INTUITIVE SURGICAL INC
$CNTA Centessa Pharmaceuticals plc
$CRNX Crinetics Pharmaceuticals, Inc.
$WAY Waystar Holding Corp.
$ARWR ARROWHEAD PHARMACEUTICALS, INC.
$SYK STRYKER CORP
$CMPX Compass Therapeutics, Inc.
$FLGT Fulgent Genetics, Inc.
$JBIO Jade Biosciences, Inc.
$IVA Inventiva S.A.
$OMDA Omada Health, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for RTW INVESTMENTS, LLC including:
Track RTW INVESTMENTS, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for RTW INVESTMENTS, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: RTW INVESTMENTS, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For RTW INVESTMENTS, LLC (SEC CIK: 1493215), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in RTW INVESTMENTS, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.